ArticleCureus2026
Temporal Patterns of Vital Signs and Their Association With 28-Day Survival in Patients With COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS) Treated With High-Flow Nasal Oxygen: A Machine Learning Model.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-flow nasal oxygen (HFNO) is widely used in COVID-19-associated acute respiratory distress syndrome (ARDS) to delay or avoid invasive mechanical ventilation (MV). However, prolonged HFNO in the presence of worsening respiratory physiology may contribute to patient self-inflicted lung injury, and the optimal timing for escalation to MV remains uncertain. This study evaluated whether temporal patterns in vital signs and the duration of HFNO exposure were associated with 28-day mortality.
methodsA retrospective observational study was conducted, including 98 adults with confirmed COVID-19 pneumonia admitted to the ICU on HFNO who subsequently required MV. Longitudinal vital signs were recorded three times daily for up to 28 days. Data were transformed into a patient-day panel to capture end-of-day clinical decision points. Feature engineering incorporated daily summaries, short-term trends, and persistence of abnormalities. Four modeling approaches-elastic-net logistic regression, discrete-time survival modeling, gradient boosting, and shallow decision trees-were trained using patient-grouped cross-validation. Model performance was assessed using precision-recall metrics and calibration.
resultsThe cohort had a mean age of 61.8±13.9 years and a mean BMI of 28.5±6 kg/m²; overall mortality was approximately 80%, with 79 patients dying during hospitalization and 19 patients surviving to 28 days. Non-survivors exhibited persistently elevated respiratory rates, progressive declines in oxygen saturation, and greater variability in cardiovascular and respiratory vital signs. Divergence in respiratory rate between survivors and non-survivors became pronounced around day 12. BMI appeared to influence respiratory rate trajectories. Across all models, prolonged HFNO duration in the presence of worsening respiratory physiology was associated with increased mortality risk. Gradient boosting achieved the highest discrimination, while logistic regression and discrete-time survival models demonstrated superior calibration and interpretability.
conclusionWorsening respiratory trajectories-rather than isolated vital-sign abnormalities-were strongly associated with mortality among patients treated with HFNO prior to MV. The interaction between prolonged HFNO exposure and physiological deterioration suggests a time-sensitive escalation window during which intubation may improve outcomes. These findings are exploratory and require validation in larger, prospective cohorts to define actionable thresholds for the optimal timing of MV in COVID-19 ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.